HeartSciences (HSCS) Receivables (2023 - 2025)
HeartSciences (HSCS) posted quarterly Receivables of $4350.0 for Q4 2025, down 70.41% on a QoQ basis from $14700.0 in Q1 2024.
HeartSciences (HSCS) Receivables (2023 - 2025) Analysis & Trends
HeartSciences (HSCS) has reported Receivables for 3 consecutive years, with $4350.0 the latest figure, recorded in Q4 2025.
- Quarterly Receivables changed N/A year-over-year to $4350.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4350.0 (changed N/A YoY) and the FY2025 annual result came in at $4350.0, changed N/A from the prior year.
- Receivables fell to $4350.0 in Q4 2025 per HSCS's latest filing, from $14700.0 in the prior quarter.
- Over the last five years, Receivables for HSCS reached as high as $14700.0 in Q1 2024 and fell as low as $3900.0 in Q4 2023.
- A 3-year average of $7650.0 and a median of $4350.0 in 2025 frame the typical range for Receivables.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 8.21 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 3.57 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 6.64 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 3.03 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 973.00 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 1.11 Bn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 4.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 1.55 Bn |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 3.80 Bn |
| 10 | HeartSciences | 6.43 Mn | 4.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,350.00 |
| Jan 31, 2024 | 14,700.00 |
| Oct 31, 2023 | 3,900.00 |